SARS-CoV-2 and the safety margins of cell-based biological medicinal products.

Authors :: Modrof J
Kerschbaum A
Farcet MR
Niemeyer D
Corman VM
Kreil TR
Source :: Biologicals : journal of the International Association of Biological Standardization [Biologicals] 2020 Nov; Vol. 68, pp. 122-124. Date of Electronic Publication: 2020 Aug 29.
Publication Year :: 2020
Abstract: With the pandemic emergence of SARS-CoV-2, the exposure of cell substrates used for manufacturing of medicines has become a possibility. Cell lines used in biomanufacturing were thus evaluated for their SARS-CoV-2 susceptibility, and the detection of SARS-CoV-2 in culture supernatants by routine adventitious virus testing of fermenter harvest tested.<br /> (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Subjects :: Animals
Antiviral Agents pharmacology
Biological Factors pharmacology
CHO Cells
COVID-19
Chlorocebus aethiops
Coronavirus Infections drug therapy
Cricetulus
Drug Evaluation, Preclinical
HEK293 Cells
Humans
Pandemics
Pneumonia, Viral drug therapy
SARS-CoV-2
Vero Cells
Betacoronavirus physiology
Coronavirus Infections metabolism
Pneumonia, Viral metabolism
Virus Replication

Language :: English
ISSN :: 1095-8320
Volume :: 68
Database :: MEDLINE
Journal :: Biologicals : journal of the International Association of Biological Standardization
Publication Type :: Academic Journal
Accession number :: 32891497
Full Text :: https://doi.org/10.1016/j.biologicals.2020.08.010